Ahmet Bilgili

Ahmet Bilgili

Auto-generated profile, based on publicly available information

Ahmet Bilgili

University of Florida

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2023 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Verified
Journal Article
Closed access
CVCarlos Alberto Valdes
Carlos Alberto Valdes
GSGriffin Stinson
Griffin Stinson
OSOmar M. Sharaf
Omar M. Sharaf
FCFabian Jimenez Contreras
Fabian Jimenez Contreras
ABAhmet Bilgili
Ahmet Bilgili
EJEric I. Jeng
Eric I. Jeng
Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is approved by the US Food and Drug Administration (FDA) for mechanical circulatory support for ≤14 days. It is unknown whether prolonged support is associated with worse outcomes. We sought to review our single-center experience with Impella 5.5 and compare outcomes based on support duration. Methods: We retrospectively reviewed adult patients (≥18 years old) supported with Impella 5.5 at our institution (May 2020 to April 2023). Patients on prolonged support (>14 days) were compared with those supported for ≤14 days. Results: There were 31 patients supported with Impella 5.5 including 14 (45.2%) supported >14 days. Median support duration for those on prolonged support was 43.5 (interquartile range [IQR] 25 to 63.5) days versus 8 (IQR 6, 13) days for those who were not ( P < 0.001). Overall, the device-related complication rate was 9.7% and did not differ between groups ( P = 0.08). Overall, 30-day postimplant survival was 71% and did not differ by support duration ( P = 0.2). In-hospital mortality was 32% and did not differ between cohorts ( P > 0.99). Among those surviving to explant ( n = 22), long-term strategy included bridge to durable ventricular assist device (18%, n = 4), cardiac transplant (55%, n = 12), and cardiac recovery (27%, n = 6). Conclusions: High-risk patients with cardiogenic shock may be supported with Impella 5.5 beyond the FDA-approved duration without increased risk of complications or mortality.

16 May 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
ABAhmet Bilgili
Ahmet Bilgili
IWIverson Williams
Iverson Williams
OSOmar M Sharaf
Omar M Sharaf
FCFabian Jimenez Contreras
Fabian Jimenez Contreras
YSYuriy Stukov
Yuriy Stukov
EJEric Jeng
Eric Jeng

1 July 2024 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Verified
Journal Article
Closed access
CVCarlos Alberto Valdes
Carlos Alberto Valdes
ABAhmet Bilgili
Ahmet Bilgili
ARAkshay Reddy
Akshay Reddy
OSOmar Sharaf
Omar Sharaf
FJFabian Jimenez-Contreras
Fabian Jimenez-Contreras
EJEric I. Jeng
Eric I. Jeng
Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is a temporary mechanical circulatory support device used for patients in cardiogenic shock. This review provides a comprehensive overview of the device’s clinical effectiveness, safety profile, patient outcomes, and relevant procedural considerations. Methods: We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the PubMed/MEDLINE database. The search query included articles available from October 6, 2022, through January 13, 2023. Our initial search identified 75 studies. All records were screened by 2 independent reviewers using the Covidence software for adherence to our inclusion criteria, and 8 retrospective cohort studies were identified as appropriate for inclusion. Results: Across the included studies, the sample size ranged from 4 to 275, with predominantly male cohorts. Indications for Impella support varied, and the duration of support ranged from 9.8 to 70 days. Overall, Impella support appeared to be associated with favorable survival rates and manageable complications in various patient populations. Complications associated with Impella use included bleeding, stroke, and device malfunctions. Two studies compared prolonged and Food and Drug Administration–approved Impella support, showing similar outcomes and adverse events. Conclusions: Impella 5.5 continues to be an attractive option for bridging patients to definitive therapy. Survival during and after Impella 5.5 was favorable for patients regardless of initial indication. However, device use was associated with several important complications, which calls for judicious use and a precontemplated exit strategy. Limitations of this literature review include biases inherent to the retrospective studies included, such as selection and publication bias.

9 July 2025 in JMIR Medical Informatics
Verified
Journal Article
Open access
JBJeremy A Balch
Jeremy A Balch
SDSasank S Desaraju
Sasank S Desaraju
VNVictoria J Nolan
Victoria J Nolan
DVDivya Vellanki
Divya Vellanki
TBTimothy R Buchanan
Timothy R Buchanan
BSBenjamin Shickel
Benjamin Shickel
Background: Operative notes are frequently mined for surgical concepts in clinical care, research, quality improvement, and billing, often requiring hours of manual extraction. These notes are typically analyzed at the document level to determine the presence or absence of specific procedures or findings (eg, whether a hand-sewn anastomosis was performed or contamination occurred). Extracting several binary classification labels simultaneously is a multilabel classification problem. Traditional natural language processing approaches—bag-of-words (BoW) and term frequency-inverse document frequency (tf-idf) with linear classifiers—have been used previously for this task but are now being augmented or replaced by large language models (LLMs). However, few studies have examined their utility in surgery. Objective: We developed and evaluated LLMs for the purpose of expediting data extraction from surgical notes. Methods: A total of 388 exploratory laparotomy notes from a single institution were annotated for 21 concepts related to intraoperative findings, intraoperative techniques, and closure techniques. Annotation consistency was measured using the Cohen κ statistic. Data were preprocessed to include only the description of the procedure. We compared the evolution of document classification technologies from BoW and tf-idf to encoder-only (Clinical-Longformer) and decoder-only (Llama 3) transformer models. Multilabel classification performance was evaluated with 5-fold cross-validation with F1-score and hamming loss (HL). We experimented with and without context. Errors were assessed by manual review. Code and implementation instructions may be found on GitHub. Results: The prevalence of labels ranged from 0.05 (colostomy, ileostomy, active bleed from named vessel) to 0.50 (running fascial closure). Llama 3.3 was the overall best-performing model (micro F1-score 0.88, 5-fold range: 0.88-0.89; HL 0.11, 5-fold range: 0.11-0.12). The BoW model (micro F1-score 0.68, 5-fold range: 0.64-0.71; HL 0.14, 5-fold range: 0.13-0.16) and Clinical-Longformer (micro F1-score 0.73, 5-fold range: 0.70-0.74; HL 0.11, 5-fold range: 0.10-0.12) had overall similar performance, with tf-idf models trailing (micro F1-score 0.57, 5-fold range: 0.55-0.59; HL 0.27, 5-fold range: 0.25-0.29). F1-scores varied across concepts in the Llama model, ranging from 0.30 (5-fold range: 0.23-0.39) for class III contamination to 0.92 (5-fold range: 0.98-0.84) for bowel resection. Context enhanced Llama’s performance, adding an average of 0.16 improvement to the F1-scores. Error analysis demonstrated semantic nuances and edge cases within operative notes, particularly when patients had references to prior operations in their operative notes or simultaneous operations with other surgical services. Conclusions: Off-the-shelf autoregressive LLMs outperformed fined-tuned, encoder-only transformers and traditional natural language processing techniques in classifying operative notes. Multilabel classification with LLMs may streamline retrospective reviews in surgery, though further refinements are required prior to reliable use in research and quality improvement.

30 January 2022 in Cureus
Verified
Journal Article
Open access
YMYusuf Mehkri
Yusuf Mehkri
KSKrishna Surapaneni
Krishna Surapaneni
BTBedirhan Tarhan
Bedirhan Tarhan
TETiffany Eisenbach
Tiffany Eisenbach
ABAhmet Bilgili
Ahmet Bilgili
KAKwame Anyane-Yeboa
Kwame Anyane-Yeboa
Pallister-Hall syndrome (PHS) is an extremely rare genetic disorder for which the diagnosis is often overlooked. The objective of this case report is to highlight how clinical features used in conjunction with brain MRI findings can lead to an expeditious diagnosis without the need for invasive measures or genetic test results. We present the case of a three-day-old infant delivered at 34 and 4/7 weeks gestation who presented with mild respiratory distress and bilious emesis in the setting of an uncomplicated gestational course and vaginal delivery with no known teratogen exposure. A diagnosis of Pallister-Hall syndrome was made on the basis of physical exam findings, hormonal abnormalities and the identification of a hypothalamic hamartoma on brain MRI. The patient underwent multiple procedures for diagnosis and management of PHS complications, including a diverting jejunostomy for a long-segment Hirschsprung’s and a laryngoscopy which identified a bifid epiglottis. The patient tolerated the interventions and did not have seizures on admission. The MRI brain detection of a hypothalamic hamartoma led to an earlier diagnosis of Pallister-Hall syndrome and thus further screening and identification of complications associated with this disorder were performed before genetic analyses or brain biopsies were obtained. Given the unique MRI features of hypothalamic hamartomas, brain MRI can be a useful tool for making an early PHS diagnosis when taken with clinical features concerning possible PHS.

5 March 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
AKAdam McLain Kase
Adam McLain Kase
JGJustyna Gleba
Justyna Gleba
JMJames L. Miller
James L. Miller
EMErin Miller
Erin Miller
JPJoachim Petit
Joachim Petit
JCJohn A. Copland
John A. Copland
Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive malignancy with poor outcomes. To investigate novel therapeutic strategies, we characterized three new metastatic prostate cancer patient derived-tumor xenograft (PDTX) models and developed 3D spheroids from each to investigate molecular targeted therapy combinations including CDK4/6 inhibitors (CDK4/6i) with AKT inhibitors (ATKi). Metastatic prostate cancer tissue was collected and three PDTX models were established and characterized using whole-exome sequencing. PDTX 3D spheroids were developed from these three PDTXs to show resistance patterns and test novel molecular-targeted therapies. CDK4/6i's were combined with AKTi's to assess synergistic antitumor response to prove our hypothesis that blockade of AKT overcomes drug resistance to CDK4/6i. This combination was evaluated in PDTX three-dimensional (3D) spheroids and in vivo experiments with responses measured by tumor volumes, PSA, and Ga-68 PSMA-11 PET-CT imaging. We demonstrated CDK4/6i's with AKTi's possess synergistic antitumor activity in three mCRPC PDTX models. These models have multiple unique pathogenic and deleterious genomic alterations with resistance to single-agent CDK4/6i's. Despite this, combination therapy with AKTi's was able to overcome resistance mechanisms. The IHC and Western blot analysis confirmed on target effects, whereas tumor volume, serum PSA ELISA, and radionuclide imaging demonstrated response to therapy with statistically significant SUV differences seen with Ga-68 PSMA-11 PET-CT. These preclinical data demonstrating antitumor synergy by overcoming single-agent CDK 4/6i as well as AKTi drug resistance provide the rational for a clinical trial combining a CDK4/6i with an AKTi in patients with mCRPC whose tumor expresses wild-type retinoblastoma 1.